Filtered By:
Cancer: Carcinoma
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 329 results found since Jan 2013.
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Neoadjuvant triplet chemotherapy with docetaxel, cisplatin plus 5-FU vs docetaxel, cisplatin plus S-1 for advanced esophageal squamous cell carcinoma: Propensity score matched analysis
CONCLUSIONS: Neoadjuvant DCS therapy for resectable advanced ESCC did not result in significantly higher clinical and pathological response than neoadjuvant DCF therapy. However, neoadjuvant DCS therapy for resectable ESCC required comparatively shorter hospital stays and incurred lower costs, making it an attractive therapeutic option.PMID:37708864 | DOI:10.1159/000533790
Source: Oncology - September 14, 2023 Category: Cancer & Oncology Authors: Junya Kitadani Toshiyasu Ojima Keiji Hayata Taro Goda Akihiro Takeuchi Shinta Tominaga Naoki Fukuda Tomoki Nakai Hiroki Yamaue Manabu Kawai Source Type: research
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma
CONCLUSIONS: After median follow-up of approximately 2 years, enfortumab vedotin maintained clinically meaningful overall survival benefit versus chemotherapy, consistent with findings from the EV-301 primary analysis; PFS and overall response benefit remained consistent. Adverse events were manageable; no new safety signals were observed.PMID:37678672 | DOI:10.1016/j.annonc.2023.08.016
Source: Ann Oncol - September 7, 2023 Category: Cancer & Oncology Authors: J E Rosenberg T Powles G P Sonpavde Y Loriot I Duran J-L Lee N Matsubara C Vulsteke D Castellano R Mamtani C Wu M Matsangou M Campbell D P Petrylak Source Type: research
Identification of an endoplasmic reticulum stress-related prognostic risk model with excellent prognostic and clinical value in oral squamous cell carcinoma
CONCLUSION: A prognostic model with high clinical application value was constructed. Immune cells, cellular stemness, and TMB may be involved in the progression of OSCC.PMID:37647077 | DOI:10.18632/aging.204983
Source: Aging - August 30, 2023 Category: Biomedical Science Authors: Mingyang Cheng Xin Fan Mu He Xianglin Dai Xiaoli Liu Jinming Hong Laiyu Zhang Lan Liao Source Type: research
A novel model based on disulfidptosis-related genes to predict prognosis and therapy of bladder urothelial carcinoma
CONCLUSION: The present study results suggest that disulfidptosis-related genes influence the prognosis of BLCA through their involvement in immune cell infiltration. Thus, these findings indicate the role of disulfidptosis in BLCA and its potential regulatory mechanisms.PMID:37541976 | DOI:10.1007/s00432-023-05235-7
Source: Cell Research - August 4, 2023 Category: Cytology Authors: Shiyong Xin Ruixin Li Junjie Su Qiong Cao Haojie Wang Zhihao Wei Guanyu Li Wang Qin Zheng Zhang Chengliang Wang Chengdong Zhang Jianguo Zhang Source Type: research
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Exp Hematol Oncol. 2023 Jul 21;12(1):63. doi: 10.1186/s40164-023-00413-2.ABSTRACTTriplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard treatments. Even though the high efficacy and good tolerance of DCF regimen were confirmed in 3 independent prospective trials, doublet CP regimen is still recommended in several guidelines based in its better safety profile with similar efficacy compared to CF regimen. We performed a propensity score-adju...
Source: Cancer Control - July 21, 2023 Category: Cancer & Oncology Authors: Stefano Kim V éronique Vendrely Ang élique Saint Thierry Andr é Pauline Vaflard Emmanuelle Samalin Simon Pernot Oliver Bouch é Mustapha Zubir J érôme Desrame Christelle de la Fouchardi ère Denis Smith Fran çois Ghiringhelli Ang élique Vienot Mari Source Type: research
